AN2 Therapeutics Inc - Asset Resilience Ratio
AN2 Therapeutics Inc (ANTX) has an Asset Resilience Ratio of 41.71% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ANTX current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how AN2 Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see AN2 Therapeutics Inc balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down AN2 Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore AN2 Therapeutics Inc (ANTX) investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $34.07 Million | 41.71% |
| Total Liquid Assets | $34.07 Million | 41.71% |
Asset Resilience Insights
- Very High Liquidity: AN2 Therapeutics Inc maintains exceptional liquid asset reserves at 41.71% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
AN2 Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare AN2 Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for AN2 Therapeutics Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for AN2 Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 61.44% | $38.06 Million | $61.95 Million | -6.18pp |
| 2024-12-31 | 67.62% | $62.27 Million | $92.09 Million | +1.56pp |
| 2023-12-31 | 66.06% | $91.65 Million | $138.74 Million | -1.07pp |
| 2022-12-31 | 67.12% | $68.84 Million | $102.56 Million | -4.01pp |
| 2021-12-31 | 71.13% | $46.46 Million | $65.32 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $4.23 Million | -- |
About AN2 Therapeutics Inc
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15… Read more